Arcadia Biosciences Stock Current Valuation
| RKDA Stock | USD 6.30 0.21 3.45% |
Valuation analysis of Arcadia Biosciences helps investors to measure Arcadia Biosciences' intrinsic value by examining its available valuation indicators, including the cash flow records, the balance sheet account changes and income statement patterns. At present, Arcadia Biosciences' Enterprise Value Over EBITDA is projected to increase significantly based on the last few years of reporting. The current year's Enterprise Value Multiple is expected to grow to 0.12, whereas Enterprise Value is projected to grow to (1.6 M). Fundamental drivers impacting Arcadia Biosciences' valuation include:
Price Book 0.8359 | Enterprise Value 2.1 M | Enterprise Value Ebitda 0.6173 | Price Sales 1.6591 | Forward PE 78.7402 |
Undervalued
Today
Please note that Arcadia Biosciences' price fluctuation is very risky at this time. Calculation of the real value of Arcadia Biosciences is based on 3 months time horizon. Increasing Arcadia Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Arcadia Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Arcadia Stock. However, Arcadia Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.3 | Real 8.03 | Target 15.0 | Hype 6.26 |
The real value of Arcadia Stock, also known as its intrinsic value, is the underlying worth of Arcadia Biosciences Company, which is reflected in its stock price. It is based on Arcadia Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Arcadia Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Arcadia Biosciences helps investors to forecast how Arcadia stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Arcadia Biosciences more accurately as focusing exclusively on Arcadia Biosciences' fundamentals will not take into account other important factors: Arcadia Biosciences Company Current Valuation Analysis
Arcadia Biosciences' Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current Arcadia Biosciences Current Valuation | 2.08 M |
Most of Arcadia Biosciences' fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Arcadia Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Arcadia Current Valuation Driver Correlations
Understanding the fundamental principles of building solid financial models for Arcadia Biosciences is extremely important. It helps to project a fair market value of Arcadia Stock properly, considering its historical fundamentals such as Current Valuation. Since Arcadia Biosciences' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Arcadia Biosciences' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Arcadia Biosciences' interrelated accounts and indicators.
Click cells to compare fundamentals
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, Arcadia Biosciences has a Current Valuation of 2.08 M. This is 99.98% lower than that of the Food Products sector and 99.98% lower than that of the Consumer Staples industry. The current valuation for all United States stocks is 99.99% higher than that of the company.
Arcadia Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Arcadia Biosciences' direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Arcadia Biosciences could also be used in its relative valuation, which is a method of valuing Arcadia Biosciences by comparing valuation metrics of similar companies.Arcadia Biosciences is currently under evaluation in current valuation category among its peers.
Arcadia Biosciences ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Arcadia Biosciences' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Arcadia Biosciences' managers, analysts, and investors.Environmental | Governance | Social |
Arcadia Fundamentals
| Return On Equity | -0.53 | ||||
| Return On Asset | -0.39 | ||||
| Profit Margin | (1.12) % | ||||
| Operating Margin | (1.15) % | ||||
| Current Valuation | 2.08 M | ||||
| Shares Outstanding | 1.36 M | ||||
| Shares Owned By Insiders | 2.70 % | ||||
| Shares Owned By Institutions | 4.69 % | ||||
| Number Of Shares Shorted | 9.1 K | ||||
| Price To Earning | 4.84 X | ||||
| Price To Book | 0.84 X | ||||
| Price To Sales | 1.66 X | ||||
| Revenue | 5.33 M | ||||
| Gross Profit | (2.22 M) | ||||
| EBITDA | (13.58 M) | ||||
| Net Income | (13.99 M) | ||||
| Cash And Equivalents | 21.23 M | ||||
| Cash Per Share | 0.96 X | ||||
| Total Debt | 1.01 M | ||||
| Debt To Equity | 0.09 % | ||||
| Current Ratio | 6.34 X | ||||
| Book Value Per Share | 7.54 X | ||||
| Cash Flow From Operations | (15.29 M) | ||||
| Short Ratio | 0.73 X | ||||
| Earnings Per Share | (6.77) X | ||||
| Price To Earnings To Growth | (0.08) X | ||||
| Target Price | 9.0 | ||||
| Number Of Employees | 21 | ||||
| Beta | 1.27 | ||||
| Market Capitalization | 8.6 M | ||||
| Total Asset | 19.7 M | ||||
| Retained Earnings | (271.84 M) | ||||
| Working Capital | 11.38 M | ||||
| Current Asset | 52.02 M | ||||
| Current Liabilities | 3.45 M | ||||
| Net Asset | 19.7 M |
About Arcadia Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Arcadia Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Arcadia Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Arcadia Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Arcadia Biosciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Arcadia Biosciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Arcadia Biosciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Arcadia Biosciences Stock:Check out Arcadia Biosciences Piotroski F Score and Arcadia Biosciences Altman Z Score analysis. For information on how to trade Arcadia Stock refer to our How to Trade Arcadia Stock guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Is Agricultural Products & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Arcadia Biosciences. If investors know Arcadia will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Arcadia Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.285 | Earnings Share (6.77) | Revenue Per Share 3.802 | Quarterly Revenue Growth (0.04) | Return On Assets (0.39) |
The market value of Arcadia Biosciences is measured differently than its book value, which is the value of Arcadia that is recorded on the company's balance sheet. Investors also form their own opinion of Arcadia Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Arcadia Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Arcadia Biosciences' market value can be influenced by many factors that don't directly affect Arcadia Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Arcadia Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Arcadia Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Arcadia Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.